746,200 Shares in Envista Holdings Corporation $NVST Bought by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd purchased a new stake in Envista Holdings Corporation (NYSE:NVST) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 746,200 shares of the company’s stock, valued at approximately $18,931,000. Envista makes up about 3.0% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its 6th largest holding. Capricorn Fund Managers Ltd owned approximately 0.46% of Envista at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL acquired a new stake in shares of Envista in the third quarter valued at about $1,664,000. First Eagle Investment Management LLC acquired a new position in Envista during the 3rd quarter worth approximately $4,329,000. Massachusetts Financial Services Co. MA boosted its holdings in Envista by 15.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock worth $72,726,000 after acquiring an additional 444,725 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Envista by 4.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 9,537,874 shares of the company’s stock worth $194,284,000 after acquiring an additional 367,363 shares during the period. Finally, Integral Health Asset Management LLC acquired a new stake in Envista in the third quarter valued at approximately $11,204,000.

Wall Street Analyst Weigh In

NVST has been the topic of a number of analyst reports. Barclays dropped their price objective on shares of Envista from $34.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, June 11th. Morgan Stanley upped their target price on shares of Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research note on Friday, April 24th. Citigroup started coverage on shares of Envista in a research note on Wednesday, April 15th. They set a “neutral” rating and a $29.00 price target on the stock. Evercore reaffirmed an “outperform” rating and set a $33.00 price target on shares of Envista in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Envista presently has an average rating of “Hold” and a consensus price target of $28.67.

Envista Stock Down 2.6%

NVST stock opened at $26.31 on Wednesday. The company has a current ratio of 2.44, a quick ratio of 2.06 and a debt-to-equity ratio of 0.47. The firm has a 50 day simple moving average of $24.85 and a 200-day simple moving average of $25.18. The company has a market capitalization of $4.28 billion, a P/E ratio of 64.18, a PEG ratio of 1.53 and a beta of 0.88. Envista Holdings Corporation has a twelve month low of $18.77 and a twelve month high of $30.42.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.05. Envista had a net margin of 2.41% and a return on equity of 7.11%. The firm had revenue of $705.50 million for the quarter, compared to analysts’ expectations of $680.03 million. During the same period in the prior year, the company posted $0.24 earnings per share. The firm’s quarterly revenue was up 14.4% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, equities research analysts predict that Envista Holdings Corporation will post 1.42 earnings per share for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.